Combination of 5α-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB

We report a first case of using a 5α-reductase inhibitor (5ARI) and combined androgen blockade (CAB) as a cytoreductive regimen before prostate brachytherapy. Prostate volume reduction with CAB is limited to approximately 40% in most cases, making it difficult to meet anatomical constraints to perfo...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Am J Clin Exp Urol
Κύριοι συγγραφείς: Muro, Yusuke, Kosaka, Takeo, Mizuno, Ryuichi, Ohashi, Toshio, Shigematsu, Naoyuki, Oya, Mototsugu
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: e-Century Publishing Corporation 2015
Θέματα:
Case Report
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4446383/
https://ncbi.nlm.nih.gov/pubmed/26069888
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια